Plus: New targets involving glycosylation, angiogenesis and more

Plus: The week’s gainers and decliners after data

University of Nottingham spinout is developing an antibody for peripheral artery disease that turns VEGF’s cancer paradigm on its head

New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD

BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more

Two gene therapies reduced the need for VEGF injections, but just the suggestion of imperfect safety sent shares of one company tumbling 

German biotech’s second deal with Biotheus marks its fifth in-licensing agreement this year with a Chinese biotech

Plus: FDA approves Coherus’ PD-1 mAb based on China data, and updates from Otsuka, Sernova, Lilly, Roche and more

EMA agency issues positive opinions on Pylclari and Ztalmy, label expansions for Opdivo and Sogroya

BioCentury’s roundup of translational news